This pilot study demonstrates that ADAM9 mRNA is associated with clinical response to HCC treatment and that there is an important link between the MICA-NKG2D system and prognosis of HCC, by showing how ADAM9 mRNA expression changes over time as HCC patients received nivolumab therapy. The gene discussed is KLRK1; the disease is hepatocellular carcinoma.